A retrospective study of survival in breast cancer patients undergoing deuterium depletion in addition to conventional therapies
English

Krempels K, Somlyai I, Gyöngyi Z, Ember I, Balog K, Abonyi O, Somlyai G
2013 Journal of Cancer Research & Therapy  
Introduction Breast cancer is a major health problem worldwide and the second most common cause of cancer-related deaths in women. Although population screening by mammography can ensure early detection of breast cancer and the rapid development of therapeutic options (i.e. surgery, radiotherapy, hormonal therapy, chemotherapy, more recently, targeted cancer drugs) provides the possibility of multidisciplinary treatment, the morbidity of breast cancer is still high [1] . Trends in mortality and
more » ... ds in mortality and morbidity did not show a decline in the United States between 2005 and 2009 [2]. Similarly, age-standardised incidence rates for breast cancer in females in Great Britain did not decrease in the past 7 to 8 years [3] . Long-term followup studies showed that the probability of relapse ranges from 30 to 85% depending on tumour stage [4]. Median survival time (MST) in advanced breast cancer defined by different clinical trials is 12 to 31 months [5] . Combined chemotherapy and targeted biological therapies are the mainstay of treatment for metastatic breast cancer Abstract There is increasing evidence that the heavy isotope of hydrogen, deuterium (D), has a pivotal role in cell signalling and that its depletion through the replacement of normal drinking water with deuterium-depleted water (DDW) results in tumour necrosis. The impact of D-depletion on breast cancer outcome was studied retrospectively. The normal daily water intake (150 ppm D) of 232 breast cancer patients was replaced with DDW (65-105 ppm D) for at least 91 days, without altering conventional treatment regimens. According to staging at initial diagnosis, patients with early stage breast cancer (n158) achieved a median survival time (MST) of 217 months (18.1 years), compared with 52 months (4.3 years) in patients with advanced disease (n74). The MST is pending in the subgroup of patients who were in remission at the start of DDW treatment; only one out of 48 patients died during the cumulative follow-up period of 221.1 years. Although single DDW treatment was effective, an outstandingly long MST of 24.4 years was attained in the subgroup of 53 patients who were treated with DDW at least twice. In comparison with published data, DDW treatment in combination with or as an extension of conventional therapies noticeably prolonged MST in certain subgroups of breast cancer patients. D-depletion may also be a highly effective therapy for preventing the recurrence of breast cancer. Furthermore, the method is safe and can be easily integrated into standard treatment regimens for breast cancer. and the goal in such cases is to maintain quality of life, ameliorate symptoms, and delay progression [5] . A wide range of information is available regarding the differences in physicochemical properties of deuterium (D) and protium (H), the two stable isotopes of hydrogen Open Access NobleResearch www.nobleresearch.org
doi:10.14312/2052-4994.2013-29 fatcat:6s7vcnbqergtfpxryycjcbpg2e